FY2027 EPS Estimates for Omnicell Cut by Zacks Research

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research lowered their FY2027 EPS estimates for shares of Omnicell in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.22 for the year, down from their previous estimate of $1.36. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share.

Other equities research analysts also recently issued reports about the company. Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Wells Fargo & Company reduced their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $52.33.

Omnicell Stock Performance

OMCL stock opened at $38.06 on Friday. The firm has a market cap of $1.76 billion, a PE ratio of 140.97, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a 50-day moving average price of $42.39 and a 200-day moving average price of $43.80. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%.

Hedge Funds Weigh In On Omnicell

Large investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its holdings in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in Omnicell in the 4th quarter worth about $37,000. Van ECK Associates Corp increased its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell during the 4th quarter worth approximately $53,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.